歌礼制药-B现涨超7% ASC47-103研究美国临床完成首批受试者给药

新浪港股
21 May
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  歌礼制药-B(01672)早盘涨幅持续扩大,股价上涨7.14%,现报6.75港元,成交额1418.78万港元。

  歌礼制药宣布,旨在评估超长效皮下注射ASC47单次给药联合司美格鲁肽在不伴有2型糖尿病的肥胖受试者中的安全性及初步疗效的随机、双盲、安慰剂对照研究(ASC47-103研究)已完成首批受试者给药。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10